Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aptinyx
With
Worldwide Clinical Trials
This is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NYX-2925 in subjects with neuropathic pain associated with diabetic peripheral neuropathy.
The study will be a 13- to 16-week study, including a 1- to 4-week Screening Period, followed by a 12- week double-blind, randomized, placebo-controlled Treatment Period.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent
Subject has diabetic peripheral neuropathy of symmetrical nature in lower extremities for ≥4 years and reports at least moderate pain over the last week
Stable diabetic and protocol allowed medication during the study
Agrees to use highly effective birth control during the study
Has not participated in an interventional study for at least 30 days and agrees not to participate in another interventional study during the study
You may not be if
Pain due to other conditions or diseases that would complicate participation in the study or pain reporting